Nanobody Functionalization and Affinity Analysis To allow for PET-imaging with a lead Nb targeting human PD-L1, both a random and site-specific coupling with NOTA chelator was performed. obtained in 95% radiochemical purity. In vivo tumor targeting studies Tezampanel at 1 h 20 post-injection revealed specific tumor uptake of 1 1.89 0.40%IA/g for the site-specific conjugate, 1.77 0.29%IA/g for the random conjugate, no nonspecific organ targeting, and excretion via the kidneys and bladder. Both strategies allowed for easily obtaining 68Ga-labeled hPD-L1 Nbs in high yields. The two conjugates were stable and showed excellent in vivo targeting. Moreover, we proved that the random lysine-conjugation is usually a valid strategy for clinical translation of the hPD-L1 Nb, despite the lysine present in the CDR. 0.05; ** 0.01; *** 0.001; Non-significant (NS). 3. Results 3.1. Nanobody Functionalization and Affinity Analysis To allow for PET-imaging with a lead Nb targeting human PD-L1, both a random and site-specific coupling with NOTA chelator was performed. The site-specific approach not only has the advantage of producing a homogenous end product [19,20], but is also important for this particular Nb, as the Nb contains besides the 0.0001; randomly-labeled; 3.0 1.4% vs. 0.3 0.1%, respectively, 0.0007). This assay confirms the specificity of the hPD-L1 Nbs for their target, but does not allow assessing affinity. Open in a separate window Physique 1 Relative amount of cell-associated activity of the (a) site-specifically and (b) randomly labeled [68Ga]Ga-NOTA-(hPD-L1) Nbs on hPD-L1POS cells at a 3 nM Nb concentration, or on hPD-L1NEG cells, or in presence of an excess of unlabeled Nb as control groups. (***, 0.001). 3.4. Affinity Assay (KD) by Cell Saturation The KD calculated from SPR was comparable for both randomly and site-specifically functionalized Nbs (non-radiolabeled compounds), as shown above. The KD was calculated from a cell saturation assay using the 68Ga-labeled probes to investigate the affinity of the radiolabeled Nbs (Physique 2). When considering the potential error margins on this experiment (on the number of cells, around the probe dilutions), the two values are considered in the same range (0.8 nM for the randomly labeled Nb, 1.2 nM for the site-specifically labeled Nb) and are in the usual range for high affinity Nbs [23]. Open in a separate window Rabbit polyclonal to GNRH Physique 2 Radioligand binding study on PD-L1POS 624-MEL cells. Cell bound activity in counts per minute (CPM) expressed as a function of the Nb concentration (nM) for (a) the site-specifically 68Ga-labeled NOTA-(hPD-L1) Nb and (b) the randomly 68Ga-labeled NOTA-(hPD-L1) Nb. 3.5. Biological Half-Life in Blood and In Vivo Stability Studies The biological half-lives in blood were 13.8 2.0 min. and 12.2 2.0 min. (NS) for the site-specifically and randomly radiolabeled Nb, respectively (Physique 3). Both Nbs exhibit a typical Nb clearance profile with a fast initial clearance phase and a slower second clearance phase. Open in a separate window Physique 3 One phase decay fitting curve representing the % of injected activity (IA) per total blood volume (TBV) over time for the site-specifically and randomly labeled [67Ga]Ga-NOTA-(hPD-L1) Nbs, showing a biological half-life of 12.4 min. and 10.8 min., respectively (NS). Up to 15 min., both the radiolabeled Nbs remained intact in plasma ( 99% of activity was intact Nb). At later time points, activity Tezampanel in plasma was too low to allow for analysis, even with 67Ga-labeled Nbs. In urine, analyses up to 120 min. revealed 90% of intact Tezampanel excreted site-specifically radiolabeled Nb compared to only 70% for the randomly radiolabeled Nb (Figures S5 and S6). 3.6. Biodistribution, In Vivo Tumor Targeting and PET/CT Imaging Table S1 summarizes the biodistribution in C57BL/6 mice of site-specifically and randomly labeled [68Ga]Ga-NOTA-(hPD-L1) Nbs. Tezampanel For both probes, ex vivo analysis 1 h 20 p.i. showed very low uptake in all organs, except in the kidneys due to renal excretion. Notably, retention in the kidneys of the site-specifically labeled hPD-L1.